Evolving Roles of Robert Maki, MD, PhD, and Marshall Posner, MD, in the Tisch Cancer Institute
Tuesday, November 10, 2015
Posted by: Andrew Law
We are pleased to announce the appointment of Robert Maki, MD, PhD, as Director of the Cancer Clinical Trials Office at Icahn School of Medicine at Mount Sinai.
Dr. Maki, a Professor of Medicine and Orthopaedics, is an internationally renowned medical oncologist with expertise in treating adults and children with sarcomas, a rare and varied group of over 50 types of cancer that arise from connective tissues. In addition to providing outstanding clinical care, Dr. Maki is a respected translational scientist whose research focuses on investigating new drugs to attack novel targets, and identifying new molecular targets that will inform future clinical trials.
As Director for Cancer Clinical Trials, Dr. Maki will extend the work of Marshall Posner, MD, in establishing a robust clinical trial infrastructure supporting investigators conducting phase I-III cancer clinical trials across the Mount Sinai Health System in the most efficient and reliable way possible. By supporting interdisciplinary efforts to develop and expand collaborative clinical and translational studies within the Tisch Cancer Institute, Dr. Maki hopes to expedite phase I clinical trials through coordination with Matthew Galsky, MD, Associate Professor of Medicine (Hematology and Medical Oncology), and will also coordinate the development of basket and umbrella clinical trials that can link Mount Sinai’s efforts in genomics to novel clinical therapies across the Health System. Dr. Maki will also continue to pursue his own sarcoma clinical research program.
In turn, Dr. Posner, who is also Professor of Medicine and Otolaryngology, will assume Dr. Maki’s role within the Tisch Cancer Institute to link genomic data to patient care. This will require new and continued collaborations between the Icahn Institute for Genomics and Multiscale Biology under the leadership of Eric Schadt, PhD, who is also the Professor and Chair of Genetics and Genomic Sciences, as well as other groups across the Health System that are interested in gene panels for rapid tumor analysis. These efforts will also include continued clinical research in the Center for Personalized Cancer Therapeutics, expanding the head and neck clinical trials activities and establishing a center for excellence in human papillomavirus (HPV) therapeutics and translational research.
We look forward to working with Dr. Maki and Dr. Posner in their new roles.